Department of Neurology and Neurosurgery, Division of Neurocritical Care, Emory School of Medicine, Emory University Hospital, 1364 Clifton Road NE, Atlanta, GA, 30322, USA.
Department of Radiology, Harvard Medical School, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Neurocrit Care. 2020 Dec;33(3):657-669. doi: 10.1007/s12028-020-00956-w.
Determining the cause of refractory seizures and/or interictal continuum (IIC) findings in the critically ill patient remains a challenge. These electrographic abnormalities may represent primary ictal pathology or may instead be driven by an underlying infectious, inflammatory, or neoplastic pathology that requires targeted therapy. In these cases, it is unclear whether escalating antiepileptic therapy will be helpful or harmful. Herein, we report the use of serial [F-18] fluorodeoxyglucose positron emission tomography (FDG-PET) coupled with induced electrographic burst suppression to distinguish between primary and secondary ictal pathologies. We propose that anesthetic suppression of hypermetabolic foci suggests clinical responsiveness to escalating antiepileptic therapy, whereas non-suppressible hypermetabolic foci are suggestive of non-ictal pathologies that likely require multimodal therapy.
We describe 6 patients who presented with electrographic findings of seizure or IIC abnormalities, severe neurologic injury, and clinical concern for confounding pathologies. All patients were continuously monitored on video electroencephalography (cvEEG). Five patients underwent at least two sequential FDG-PET scans of the brain: one in a baseline state and the second while under electrographic burst suppression. FDG-avid loci and EEG tracings were compared pre- and post-burst suppression. One patient underwent a single FDG-PET scan while burst-suppressed.
Four patients had initially FDG-avid foci that subsequently resolved with burst suppression. Escalation of antiepileptic therapy in these patients resulted in clinical improvement, suggesting that the foci were related to primary ictal pathology. These included clinical diagnoses of electroclinical status epilepticus, new-onset refractory status epilepticus, stroke-like migraine attacks after radiotherapy, and epilepsy secondary to inflammatory cerebral amyloid angiopathy. Conversely, two patients with high-grade EEG abnormalities had FDG-avid foci that persisted despite burst suppression. The first presented with a poor examination, fever, and concern for encephalitis. Postmortem pathology confirmed suspicion of herpes simplex virus encephalitis. The second patient presented with concern for checkpoint inhibitor-induced autoimmune encephalitis. The persistence of the FDG-avid focus, despite electrographic burst suppression, guided successful treatment through escalation of immunosuppressive therapy.
In appropriately selected patients, FDG-PET scans while in burst suppression may help dissect the underlying pathophysiologic cause of IIC findings observed on EEG and guide tailored therapy.
在危重症患者中,确定难治性癫痫发作和/或发作间连续状态(IIC)的原因仍然具有挑战性。这些脑电图异常可能代表原发性癫痫样病理,也可能由潜在的感染、炎症或肿瘤性病变驱动,需要靶向治疗。在这些情况下,尚不清楚增加抗癫痫治疗是否会有帮助或有害。在此,我们报告了使用连续[F-18]氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)与诱导的脑电图爆发抑制相结合来区分原发性和继发性癫痫样病理。我们提出,麻醉抑制高代谢病灶表明对增加抗癫痫治疗有临床反应,而不可抑制的高代谢病灶提示可能需要多模式治疗的非癫痫样病变。
我们描述了 6 名患者,他们表现出癫痫发作或 IIC 异常的脑电图发现、严重的神经损伤和混杂性病变的临床关注。所有患者均连续进行视频脑电图(cvEEG)监测。5 名患者进行了至少两次脑 FDG-PET 扫描:一次在基线状态,第二次在脑电图爆发抑制下进行。在爆发抑制前后比较 FDG 摄取病灶和脑电图描记。一名患者在爆发抑制下进行了单次 FDG-PET 扫描。
4 名患者最初有 FDG 摄取病灶,随后在爆发抑制下消退。在这些患者中增加抗癫痫治疗导致了临床改善,这表明病灶与原发性癫痫样病理有关。这些包括临床诊断为电临床癫痫持续状态、新诊断的难治性癫痫持续状态、放疗后类似中风的偏头痛发作和炎症性脑淀粉样血管病继发的癫痫。相反,两名脑电图异常高的患者尽管进行了爆发抑制,仍有 FDG 摄取病灶。第一位患者表现为检查不佳、发热和对脑炎的关注。尸检病理证实了单纯疱疹病毒脑炎的怀疑。第二位患者表现为担心免疫检查点抑制剂诱导的自身免疫性脑炎。尽管脑电图爆发抑制,但 FDG 摄取病灶的持续存在指导了通过增加免疫抑制治疗成功治疗。
在适当选择的患者中,在爆发抑制下进行 FDG-PET 扫描可能有助于剖析 EEG 上观察到的 IIC 发现的潜在病理生理原因,并指导量身定制的治疗。